In recent trading, shares of Emergent BioSolutions Inc have crossed above the average analyst 12-month target price of $45.75, changing hands for $46.44/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
Investors in Emergent BioSolutions Inc saw new options begin trading this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EBS options chain for the new February 16th contracts and identified one put and one call contract of particular interest.
In recent trading, shares of Emergent BioSolutions Inc have crossed above the average analyst 12-month target price of $44.25, changing hands for $45.48/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Health Canada approves Anthrasil® under Extraordinary Use New Drug Regulations
These lesser-known diagnostic and life sciences firms are involved in areas from genetic tools to telemedicine.
Facility Includes an Accordion Feature Enabling $100 Million of Additional Capacity for a Total of $300 Million
Ionis retained all rights to inotersen and IONIS-FB-LRx as part of reprioritizing its pipeline and a strategic review of its Rare Diseases business.
